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Fragile X syndrome, a common cause of intellectual disability and autism, is thought to occur due to abnormal
regulation of neuronal protein synthesis. A study byOsterweil et al. (2013), in this issue, demonstrates that the
HMG-CoA reductase inhibitor lovastatin can normalize protein synthesis and also reduce audiogenic
seizures in Fmr1 knockout mice.The autism spectrum disorders (ASDs)
are characterized by a suite of neuropsy-
chiatric phenotypes that include ab-
normal social behavior, restricted behav-
ioral repertoires, and dysfunctions of
language. Although they are not consid-
ered a core component of ASDs, approx-
imately 30% of ASD patients have a
seizure disorder, a marked increase over
the incidence of epilepsy in the general
population. Diagnosis of ASDs has been
on an alarming rise, with recent epidemio-
logical estimates of up to 1/54 males
being affected (Baio, 2012). Because
most ASDs have not been pathophysio-
logically attributable to single biological
lesions, the therapy for ASD patients is
primarily supportive, and the develop-
ment of mechanism-based therapeutics
has remained a major challenge. One
approach toward getting a biological
foothold into complex neurological condi-
tions such as ASDs has been to study
single gene disorders, of which ASD
phenotypes are a common component.
Approximately 5%–7% of ASDs occur
as part of so-called ‘‘syndromic autism’’
and include fragile X syndrome (FXS),
tuberous sclerosis complex (TSC), and
PTEN-associated macrocephaly/autism,
among others. Remarkably, many of
these disorders are caused by mutations
in pathways that regulate mRNA transla-
tion, strongly suggesting that the regula-
tion of protein synthesis is implicated
in ASD pathophysiology. In this issue
of Neuron, Osterweil et al. (2013) have
exploited this approach, building on
years of mechanistic investigations, to
test a rationally conceived, though unex-
pected, therapeutic for neurophysiolog-212 Neuron 77, January 23, 2013 ª2013 Elseical derangements in a mouse model of
FXS: the HMG-CoA reductase inhibitor,
lovastatin.
FXS is estimated to affect 1/4000
males, representing the most common in-
herited form of intellectual disability
worldwide (Santoro et al., 2012). FXS
results from expansions of a CGG trinu-
cleotide repeat in the 50 untranslated
region of the fragile X mental retardation
gene 1 (FMR1) resulting in the silencing
and loss of expression of the FMRP
protein. FMRP is an RNA binding protein
that is highly expressed in neurons and
is estimated to bind 4% of all brain
RNAs (Ashley et al., 1993; Darnell et al.,
2011). Animal models for FMRP have
been made in mice, flies, and zebrafish
with convergent streams of data pointing
to a role for FMRP as a translational
repressor. Indeed, FMRP knockout mice
(Fmr1/y) demonstrate a significant
increase in global protein synthesis in
the brain, also reflected by changes in
protein synthesis at the synapse (‘‘local
translation’’) (Bassell and Warren, 2008).
These findings are supported by the
demonstration of impaired synaptic plas-
ticity, alterations in dendritic morphology,
and ultimately, neurocognitive deficits
in FMRP mutants. Overall, these data
have established a major role for FMRP
in the regulation and maintenance of
synaptic function. Long-term depression
(LTD) is a form of hippocampal synaptic
plasticity that requires the function of
a family of metabotropic glutamate recep-
tors (mGLuRs), most conspicuously,
mGluR5. This has previously led the
authors, and others, to directly test the
role of mGluRs in mediating FMRP-vier Inc.related synaptic phenotypes (Bear et al.,
2004). Indeed, genetic reduction of
mGluR5 normalized the increase in
protein synthesis in Fmr1/y mice, sug-
gesting that FMRP mediates its effects
through mGluR signaling (Do¨len et al.,
2007). The precisemechanisms of FMRP-
mediated translational control (through
mGluR or otherwise) remain unclear;
however, experiments from several labs
have suggested that both the mTOR and
MAP kinase signaling cascades may be
involved (Gross et al., 2012).
The phosphorylation of the Ras-depen-
dent MAP kinases ERK1/2 can be sup-
pressed pharmacologically with the
HMG-CoA reductase inhibitor lovastatin.
Statins block the mevalonate pathway
thus inhibiting cholesterol biosynthesis
and the farnesylation of Ras (and other
proteins). Farnesylation is important for
Ras’ association with the membrane
and, subsequently, its full activation.
Suppression of ERK1/2 can normalize
increases in protein synthesis in Fmr1/y
mice, supporting a role for ERK activity
in mediating the suppressive effects of
FMRP on translation. Despite the normal-
ization of FMRP-related phenotypes by
suppression of activated ERK1/2, the
kinases do not appear to be overactivated
in Fmr1/y mice. Because of the effec-
tiveness of ERK1/2 suppression on
protein synthesis in Fmr1/y mice, Oster-
weil et al. (2013) hypothesized that sup-
pression of farnesylation might effectively
block the neurological phenotypes of
Fmr1/y mice, presumably through Ras-
related changes in ERK1/2 activation.
The authors show that in hippocampal
slices, either farnesyl thiosalicylic acid
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lovastatin (an upstream metabolite inhib-
itor) reduces ERK1/2 phosphorylation
and normalizes both global protein
synthesis and the defective hippocampal
LTD in Fmr1/y mice. Consistent with
previous experiments, the authors found
no increase in basal activation of ERK1/2
levels in the Fmr1/y background. Thus,
the authors attribute lovastatin’s effec-
tiveness to a hypersensitivity of Fmr1/y
mice to ERK1/2 activity.
As alluded to above, epilepsy is comor-
bid in about 30% of patients with ASDs
but only in about 14% of FXS patients—
still a substantial increase over the
general population. In FXS patients,
seizures are typically of the complex
partial type, start between 4 and 10 years
of age, and resolve during childhood.
Importantly, the presence of seizures
appears to correlate with increased risk
of ASD (Berry-Kravis et al., 2010). The
pathophysiological relationships between
ASD and epileptiform activity remain
largely unclear. Are epilepsy and neuro-
psychiatric features of ASD indepen-
dently adverse outcomes of a concomi-
tant neuropathological mechanism or,
alternatively, do the two phenotypes syn-
ergize to exacerbate overall neurological
outcomes? Increased ERK1/2 activity
has been previously shown to increase
spontaneous discharges in the CA3
region of the hippocampus (Zhao et al.,
2004). In a set of complementary experi-
ments, Osterweil et al. (2013) show that
lovastatin could block most of the epilep-
tiform bursting in the CA3 region of the
hippocampus and reduce spontaneous
action potentials in the visual cortex of
Fmr1/y mice.
Finally, the authors show that lova-
statin administered either orally or by
injection was able to inhibit the ex-
pression of audiogenic seizures (AGS)
in Fmr1/y mice. An AGS is an evoked
brainstem reflex consisting of a run-
ning fit driven by activation of brainstem
nuclei with no concordant EEG hyper-
excitability at the cortical level. Thus,
AGS may be a reflection of hyperexcit-
ability, but it is of unclear relation to
most forms of human epilepsy. Never-
theless, AGS represents a persuasivephenotypic manifestation of the overall
hyperexcitability in Fmr1/y mice, and
the response to lovastatin in Fmr1/y
mice lends further credence to the
potential effectiveness of the drug in
this context.
This study opens up many interesting
areas of further inquiry; for example, the
detailed mechanisms by which lovastatin
works to reduce hyperexcitability are not
yet clear. The authors hypothesize that
the suppression of ERK1/2 is at least
partially responsible. Given that ERK1/2
levels are not elevated in Fmr1/y mice
and that FTS or lovastatin affects multiple
targets, this suggests that the observed
suppression of ERK1/2 may not fully
explain the efficacy of either compound.
The greatest morbidity associated with
FXS is intellectual disability and behav-
ioral problems. Future studies will be
required to address the responsiveness
of the neurocognitive phenotypes in
Fmr1/y mice to lovastatin treatment. It
will be very interesting to see whether
lovastatin can correct exaggerated
mGluR-LTD, increased dendritic spine
density, and impaired learning in the
Fmr1/y mouse model. Ultimately, the
findings reported in Osterweil et al.
(2013) will be best judged by the results
of a clinical trial in children with FXS.
Indeed, lovastatin has already been used
in clinical trials for neurofibromatosis I
(NF1), a condition in which Ras is dysre-
gulated (Li et al., 2005; Acosta et al.,
2011). Lovastatin is particularly exciting
as a potential therapy in FXS because
the drug has already been in wide use
for years and is approved for use in chil-
dren with hypercholesterolemia, thus
expediting the tests of its effectiveness
in FXS patients.
Based on other clinical trials in neuro-
developmental disorders, it is likely that
subgroups of patients will respond better
to different targeted agents, even in
a homogeneous disorder such as FXS.
One would predict, then, that ERK hyper-
activity could potentially be a biomarker
for subsets of FXS patients that could
benefit from lovastatin treatment (Weng
et al., 2008). These results suggest that
ERK activity could potentially act as
a surrogate marker of drug responsive-Neuron 77ness during treatment with lovastatin
and related drugs.
In summary, rational therapies for ASDs
are greatly needed. Several clinical
trials are ongoing in syndromic causes of
ASD including FXS, TSC, and Rett
syndrome. By linking FMRP-mediated
increase in protein synthesis to the
ERK1/2 pathway, Osterweil et al. (2013)
have harnessed rational hypotheses
based on animal models toward testing
a relatively seasoned and safe therapeutic
for a novel and previously unconsidered
translational application. This potential
treatment may hold great promise for
patients with FXS and perhaps those
with other forms of hyperexcitability and
ASD as well.REFERENCES
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